Allergen-Specific Immunotherapy in Asthma

Current Treatment Options in Allergy

Volumn 1, Issue 2, 2014, Pages 213-219

  Jutel, Marek ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b ALL MED Medical Research Institute   (Poland)

Author keywords

Allergen specific immunotherapy; Asthma; Bronchodilators; Inhaled corticosteroids; LABA; Long acting bronchodilators; Omalizumab; SCIT; SLIT

Indexed keywords

EID: 84928382830     PISSN: None     EISSN: 21963053     Source Type: Journal    
DOI: 10.1007/s40521-014-0013-1     Document Type: Review

References (35)

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–78. DOI: 10.1183/09031936.00138707
2. Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835–46. DOI: 10.1111/j.1398-9995.2012.02832.x
3. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18(5):736–49. DOI: 10.1038/nm.2754
4. Kaczorowski M, Jutel M. Human T regulatory cells: on the way to cognition. Arch Immunol Ther Exp (Warsz). 2013;61(3):229–36. DOI: 10.1007/s00005-013-0217-2
5. Jutel M, Akdis CA. T-cell subset regulation in atopy. Curr Allergy Asthma Rep. 2011;11(2):139–45. DOI: 10.1007/s11882-011-0178-7
6. Wang W, Li JJ, Foster PS, Hansbro PM, Yang M. Potential therapeutic targets for steroid-resistant asthma. Curr Drug Targets. 2010;11(8):957–70. DOI: 10.2174/138945010791591412
7. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med. 2008;178(10):1009–16. DOI: 10.1164/rccm.200804-494OC
8. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci. 2010;31(7):335–43. DOI: 10.1016/j.tips.2010.04.009
9. Kopp MV. Omalizumab: anti-IgE therapy in allergy. Curr Allergy Asthma Rep. 2011;11(2):101–6. DOI: 10.1007/s11882-010-0173-4
10. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96 e1283. Comprehensive report of the AAAAI and EAACI consensus on AIT.
11. Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425–33. DOI: 10.2332/allergolint.13-RAI-0608
12. Calderon MA, Casale T, Cox L, Akdis CA, Burks AW, Nelson HS, et al. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2013;68(7):825–8. DOI: 10.1111/all.12180
13. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: the present and the future. Hum Vaccin Immunother. 2012;8(10):1534–43. DOI: 10.4161/hv.22064
14. Lin SY, Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Ward D, et al. Agency for healthcare research and quality (US); 2013 Mar. Report No.: 13–EHC061-EF. AHRQ Comparative Effectiveness Reviews; 2013. Updated systematic review providing a overview of efficacy of SLIT and SCIT including asthma.
15. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278–88. Systematic review on the efficacy of SLIT in the treatment of allergic rhinitis and asthma, also addressing optimal dosing strategies. DOI: 10.1001/jama.2013.2049
16. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–62. DOI: 10.1016/j.jaci.2012.07.053
17. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76. DOI: 10.1016/j.jaci.2010.06.047
18. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186. DOI: CD001186
19. Stelmach I, Sobocinska A, Majak P, Smejda K, Jerzynska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol. 2012;109(4):274–8. Interesting study providing evidence on the optimal duration of AIT. DOI: 10.1016/j.anai.2012.07.015
20. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157(3):288–98. DOI: 10.1159/000327566
21. Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2013. doi:10.1002/lary.24295.
22. De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. Eur Rev Med Pharmacol Sci. 2013;17(16):2225–31.
23. Peng W, Liu E. Factors influencing the response to specific immunotherapy for asthma in children aged 5–16 years. Pediatr Int. 2013;55(6):680–4. DOI: 10.1111/ped.12175
24. Rosewich M, Arendt S, El Moussaoui S, Schulze J, Schubert R, Zielen S. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children. Pediatr Allergy Immunol. 2013;24(5):434–40. DOI: 10.1111/pai.12068
25. Marogna M, Braidi C, Bruno ME, Colombo C, Colombo F, Massolo A, et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr). 2012;41(4):216–24. DOI: 10.1016/j.aller.2012.07.004
26. Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2012;130(4):886–93 e885.
27. Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy. 2011;66 Suppl 95:55–6. DOI: 10.1111/j.1398-9995.2011.02641.x
28. Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131(6):1155–67. Comprehensive systematic review of AIT in the pediatric population. DOI: 10.1542/peds.2013-0343
29. Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol. 2012;25(1):193–206.
30. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55. DOI: 10.1016/j.jaci.2010.09.034
31. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–11. Comprehensive report addressing the issue of safety of AIT. DOI: 10.1111/j.1398-9995.2011.02761.x
32. Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2011;67(3):312–20. DOI: 10.1111/j.1398-9995.2011.02758.x
33. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609. DOI: 10.1378/chest.06-1425
34. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol. 2009;124(1):157–61. e151-132. DOI: 10.1016/j.jaci.2009.04.015
35. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol. 2009;102(1):22–8. DOI: 10.1016/S1081-1206(10)60103-2